Loren Gragert
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Loren Gragert has a total of 369 co-authors. Here are the top co-authors by number of shared publications:
- Martin Maiers
Center for International Blood and Marrow Transplant Research, NMDP, Minneapolis, MN
21 shared publications William Klitz
9 shared publications- Yoram Louzoun
Department of Mathematics, Bar-Ilan University, Ramat Gan, Israel
6 shared publications - Sapir Israeli
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
5 shared publications - Evan P. Kransdorf
Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
4 shared publications Martin Maiers
National Marrow Donor Program/Be The Match, Minneapolis, MN, United States; Center for International Blood and Marrow Transplant Research, Minneapolis, MN, United States
4 shared publications
Latest Publications
- Open Access
- 9 August 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (10) , 111810
GRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches
- 9 August 2026
- Published by Elsevier in Human Immunology
- Vol. 87 (10) , 111810
Open AccessGRIMM-II: A two-stage real-time algorithm for nine-locus HLA imputation and matching with up to three mismatches
- Open Access
The Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context
Standardised data representation is fundamental to the integrity, interoperability and reproducibility of immunogenetics and histocompatibility testing. While well‐established standards such as the genotype list (GL) String, histoimmunogenetics markup language (HML) and minimum information for reporting next‐generation sequence genotyping exist for encoding HLA genotyping results, no equivalent syntax currently exists for describing phenotype‐ or antigen‐level information that underlies antibody testing and immunological risk assessment. We introduce the phenotype list (PL) String grammar and the phenotype list string code (PLSC) syntax, structured, machine‐readable grammars designed to represent antigen‐ and protein‐level data across three contexts: (1) the HLA phenotype composition of assay reagents, (2) test results derived from those reagents and (3) clinical interpretations of HLA antibody specificities. PL String extends the hierarchical logic of the GL String grammar, while adapting a subset of GL String delimiters and rules to describe ambiguity, heterodimeric relationships and phenotypic composition. PL String incorporates explicit namespace definitions (e.g., World Health Organization HLA Nomenclature Committee for Factors of the HLA System, Organ Procurement and Transplantation Network, Eurotransplant and NMDP) to ensure traceability and compatibility with existing regulatory and operational frameworks. By harmonising how HLA phenotypic and antibody data are encoded, PL Strings enable automated data exchange between laboratories, registries and information systems, reducing transcription errors and improving computational interpretation. This new grammar establishes a foundation for interoperable representation of serologic and functional HLA data, facilitating reproducible research and enhancing clinical decision support in transplantation and immunogenetics. Technical specifications for PL Strings and PLSCs are available at plstring.org .
Open AccessThe Phenotype List String Grammar for Enhanced Protein and Antigen Reporting in the Immunogenetic Context
Standardised data representation is fundamental to the integrity, interoperability and reproducibility of immunogenetics and histocompatibility testing. While well‐established standards such as the genotype list (GL) String, histoimmunogenetics markup language (HML) and minimum information for reporting next‐generation sequence genotyping exist for encoding HLA genotyping results, no equivalent syntax currently exists for describing phenotype‐ or antigen‐level information that underlies antibody testing and immunological risk assessment. We introduce the phenotype list (PL) String grammar and the phenotype list string code (PLSC) syntax, structured, machine‐readable grammars designed to represent antigen‐ and protein‐level data across three contexts: (1) the HLA phenotype composition of assay reagents, (2) test results derived from those reagents and (3) clinical interpretations of HLA antibody specificities. PL String extends the hierarchical logic of the GL String grammar, while adapting a subset of GL String delimiters and rules to describe ambiguity, heterodimeric relationships and phenotypic composition. PL String incorporates explicit namespace definitions (e.g., World Health Organization HLA Nomenclature Committee for Factors of the HLA System, Organ Procurement and Transplantation Network, Eurotransplant and NMDP) to ensure traceability and compatibility with existing regulatory and operational frameworks. By harmonising how HLA phenotypic and antibody data are encoded, PL Strings enable automated data exchange between laboratories, registries and information systems, reducing transcription errors and improving computational interpretation. This new grammar establishes a foundation for interoperable representation of serologic and functional HLA data, facilitating reproducible research and enhancing clinical decision support in transplantation and immunogenetics. Technical specifications for PL Strings and PLSCs are available at plstring.org .
- Open Access
GRIMM-II: A Two-Stage Real-Time Algorithm for Nine-Locus HLA Imputation and Matching with Up to Three Mismatches
Background: The success of hematopoietic stem cell transplantation (HSCT) depends critically on human leukocyte antigen (HLA) matching between donor and recipient. While traditional matching focuses on five classical HLA loci (A, B, C, DRB1, DQB1), clinical practice increasingly considers extended typing at nine loci, including DPA1, DQA1, DPB1, and DRB3/4/5. Furthermore, emerging evidence supports transplantation with up to three HLA mismatches under post-transplant cyclophosphamide (PTCy) regimens. However, current donor search algorithms cannot efficiently identify donors with multiple mismatches across extended HLA loci in real-time. Methods: We developed GRIMM-II (GRaph IMputation and Matching, version II), which comprises two novel algorithms: ML-GRIM (Multi-Locus GRIM) for HLA imputation across multiple loci, and ML-GRMA (Multi-Locus GRMA) for real-time donor-patient matching with up to three mismatches. Both algorithms employ a two-stage approach that combines efficient candidate reduction through graph-theoretic frameworks with detailed genotype comparison. ML-GRIM partitions genotypes into class I (HLA-A, B, C) and class II (remaining loci) components, enabling memory-efficient storage and rapid candidate identification. ML-GRMA searches a pre-imputed donor graph composed of donor genotypes and their sub-components, then computes asymmetric graft-versus-host (GvH) and host-versus-graft (HvG) mismatch probabilities to provide clinically relevant compatibility assessments. Both imputation and matching tools are available as a web application at https://grimmard.math.biu.ac.il/ and through GitHub repositories at https://github.com/nmdp-bioinformatics/py-graph-imputation (imputation) and https://github.com/nmdp-bioinformatics/py-graph-match (matching). Results: We validated ML-GRMA and ML-GRIM using the WMDA3 (World Marrow Donor Association) validation dataset, successfully reproducing all previously reported matches while identifying numerous additional candidate donors not detected by previous algorithms. Further validation of ML-GRMA using 3,000 patients with artificially introduced mismatches (0-3 allele substitutions) demonstrated 100% sensitivity and specificity in identifying matching donors at expected mismatch levels. We validated ML-GRIM using simulated nine-locus typings derived from 8,078,224 US donors in the NMDP registry. The algorithm successfully imputed genotypes across variable numbers of typed loci while incorporating multiethnic haplotype frequencies. The algorithm achieved real-time performance with typical imputation times under one second and matching times of 1-13 seconds per patient for up to three mismatches, even when searching databases exceeding 8 million donors. Notably, ML-GRMA identified substantially more potentially suitable donors than traditional algorithms by accounting for the biological reality that GvH and HvG mismatches often differ, particularly for donors homozygous at specific loci. To evaluate ML-GRIM performance with low-resolution typing, we tested it on simulated 3-locus typings from the same population. The resulting imputation accuracy correlated with the mutual information between typed loci and complete genotypes. Conclusions: GRIMM-II provides a scalable, memory-efficient solution for nine-locus HLA imputation and real-time identification of donors with up to three mismatches. The graph-based framework supports dynamic registry updates and can readily accommodate additional HLA loci and matching criteria as clinical knowledge evolves. By expanding the pool of acceptable donors while maintaining computational efficiency, GRIMM-II addresses a critical need in contemporary transplantation practice, particularly for patients from underrepresented ethnic minorities who face lower probabilities of finding perfectly matched donors.
Open AccessGRIMM-II: A Two-Stage Real-Time Algorithm for Nine-Locus HLA Imputation and Matching with Up to Three Mismatches
Background: The success of hematopoietic stem cell transplantation (HSCT) depends critically on human leukocyte antigen (HLA) matching between donor and recipient. While traditional matching focuses on five classical HLA loci (A, B, C, DRB1, DQB1), clinical practice increasingly considers extended typing at nine loci, including DPA1, DQA1, DPB1, and DRB3/4/5. Furthermore, emerging evidence supports transplantation with up to three HLA mismatches under post-transplant cyclophosphamide (PTCy) regimens. However, current donor search algorithms cannot efficiently identify donors with multiple mismatches across extended HLA loci in real-time. Methods: We developed GRIMM-II (GRaph IMputation and Matching, version II), which comprises two novel algorithms: ML-GRIM (Multi-Locus GRIM) for HLA imputation across multiple loci, and ML-GRMA (Multi-Locus GRMA) for real-time donor-patient matching with up to three mismatches. Both algorithms employ a two-stage approach that combines efficient candidate reduction through graph-theoretic frameworks with detailed genotype comparison. ML-GRIM partitions genotypes into class I (HLA-A, B, C) and class II (remaining loci) components, enabling memory-efficient storage and rapid candidate identification. ML-GRMA searches a pre-imputed donor graph composed of donor genotypes and their sub-components, then computes asymmetric graft-versus-host (GvH) and host-versus-graft (HvG) mismatch probabilities to provide clinically relevant compatibility assessments. Both imputation and matching tools are available as a web application at https://grimmard.math.biu.ac.il/ and through GitHub repositories at https://github.com/nmdp-bioinformatics/py-graph-imputation (imputation) and https://github.com/nmdp-bioinformatics/py-graph-match (matching). Results: We validated ML-GRMA and ML-GRIM using the WMDA3 (World Marrow Donor Association) validation dataset, successfully reproducing all previously reported matches while identifying numerous additional candidate donors not detected by previous algorithms. Further validation of ML-GRMA using 3,000 patients with artificially introduced mismatches (0-3 allele substitutions) demonstrated 100% sensitivity and specificity in identifying matching donors at expected mismatch levels. We validated ML-GRIM using simulated nine-locus typings derived from 8,078,224 US donors in the NMDP registry. The algorithm successfully imputed genotypes across variable numbers of typed loci while incorporating multiethnic haplotype frequencies. The algorithm achieved real-time performance with typical imputation times under one second and matching times of 1-13 seconds per patient for up to three mismatches, even when searching databases exceeding 8 million donors. Notably, ML-GRMA identified substantially more potentially suitable donors than traditional algorithms by accounting for the biological reality that GvH and HvG mismatches often differ, particularly for donors homozygous at specific loci. To evaluate ML-GRIM performance with low-resolution typing, we tested it on simulated 3-locus typings from the same population. The resulting imputation accuracy correlated with the mutual information between typed loci and complete genotypes. Conclusions: GRIMM-II provides a scalable, memory-efficient solution for nine-locus HLA imputation and real-time identification of donors with up to three mismatches. The graph-based framework supports dynamic registry updates and can readily accommodate additional HLA loci and matching criteria as clinical knowledge evolves. By expanding the pool of acceptable donors while maintaining computational efficiency, GRIMM-II addresses a critical need in contemporary transplantation practice, particularly for patients from underrepresented ethnic minorities who face lower probabilities of finding perfectly matched donors.
- Open Access
- 19 December 2025
- Published by Elsevier in Human Immunology
- Vol. 87 (2) , 111639
Prolonged wait times among highly sensitized HLA-B46 homozygous kidney transplant candidates
- 19 December 2025
- Published by Elsevier in Human Immunology
- Vol. 87 (2) , 111639
Open AccessProlonged wait times among highly sensitized HLA-B46 homozygous kidney transplant candidates
- Top Cited Papers
- 13 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8100) , 205-217
Multi-omics analysis of a pig-to-human decedent kidney xenotransplant
Organ shortage remains a major challenge in transplantation, and gene-edited pig organs offer a promising solution1–3. Despite gene-editing, the immune reactions following xenotransplantation can still cause transplant failure4. To understand the immunological response of a pig-to-human kidney xenotransplantation, we conducted large-scale multi-omics profiling of the xenograft and the host’s blood over a 61-day procedure in a brain-dead human (decedent) recipient. Blood plasmablasts, natural killer (NK) cells, and dendritic cells increased between postoperative day (POD)10 and 28, concordant with expansion of IgG/IgA B-cell clonotypes, and subsequent biopsy-confirmed antibody-mediated rejection (AbMR) at POD33. Human T-cell frequencies increased from POD21 and peaked between POD33-49 in the blood and xenograft, coinciding with T-cell receptor diversification, expansion of a restricted TRBV2/J1 clonotype and histological evidence of a combined AbMR and cell-mediated rejection at POD49. At POD33, the most abundant human immune population in the graft was CXCL9+ macrophages, aligning with IFN-γ-driven inflammation and a Type I immune response. In addition, we see evidence of interactions between activated pig-resident macrophages and infiltrating human immune cells. Xenograft tissue showed pro-fibrotic tubular and interstitial injury, marked by S100A65, SPP16 (Osteopontin), and COLEC117, at POD21–POD33. Proteomics profiling revealed human and pig complement activation, with decreased human component after AbMR therapy with complement inhibition. Collectively, these data delineate the molecular orchestration of human immune responses to a porcine kidney, revealing potential immunomodulatory targets for improving xenograft survival.
- 13 November 2025
- Published by Springer Nature in Nature
- Vol. 650 (8100) , 205-217
Top Cited PapersMulti-omics analysis of a pig-to-human decedent kidney xenotransplant
Organ shortage remains a major challenge in transplantation, and gene-edited pig organs offer a promising solution1–3. Despite gene-editing, the immune reactions following xenotransplantation can still cause transplant failure4. To understand the immunological response of a pig-to-human kidney xenotransplantation, we conducted large-scale multi-omics profiling of the xenograft and the host’s blood over a 61-day procedure in a brain-dead human (decedent) recipient. Blood plasmablasts, natural killer (NK) cells, and dendritic cells increased between postoperative day (POD)10 and 28, concordant with expansion of IgG/IgA B-cell clonotypes, and subsequent biopsy-confirmed antibody-mediated rejection (AbMR) at POD33. Human T-cell frequencies increased from POD21 and peaked between POD33-49 in the blood and xenograft, coinciding with T-cell receptor diversification, expansion of a restricted TRBV2/J1 clonotype and histological evidence of a combined AbMR and cell-mediated rejection at POD49. At POD33, the most abundant human immune population in the graft was CXCL9+ macrophages, aligning with IFN-γ-driven inflammation and a Type I immune response. In addition, we see evidence of interactions between activated pig-resident macrophages and infiltrating human immune cells. Xenograft tissue showed pro-fibrotic tubular and interstitial injury, marked by S100A65, SPP16 (Osteopontin), and COLEC117, at POD21–POD33. Proteomics profiling revealed human and pig complement activation, with decreased human component after AbMR therapy with complement inhibition. Collectively, these data delineate the molecular orchestration of human immune responses to a porcine kidney, revealing potential immunomodulatory targets for improving xenograft survival.
- Open Access
- 2 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (6) , 1226-1234
Balancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch
- 2 December 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (6) , 1226-1234
Open AccessBalancing equity and human leukocyte antigen matching in deceased-donor kidney allocation with eplet mismatch
- Open Access
- 14 May 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (3) , 110813
High-resolution HLA genotyping improves PIRCHE-II assessment of molecular mismatching in kidney transplantation
- 14 May 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (3) , 110813
Open AccessHigh-resolution HLA genotyping improves PIRCHE-II assessment of molecular mismatching in kidney transplantation
- 17 February 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 122, 106036
Exploration of potential immune mechanisms in cervical dystonia
- 17 February 2024
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 122, 106036
Exploration of potential immune mechanisms in cervical dystonia
- Open Access
- 21 October 2023
- Published by Elsevier in Human Immunology
- Vol. 84 (12) , 110721
Combined imputation of HLA genotype and self-identified race leads to better donor-recipient matching
- 21 October 2023
- Published by Elsevier in Human Immunology
- Vol. 84 (12) , 110721
Open AccessCombined imputation of HLA genotype and self-identified race leads to better donor-recipient matching
- 5 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 387-393
HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation
- 5 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 387-393
HLA sensitization is associated with an increased risk of primary graft dysfunction after heart transplantation